Contents

**Preface XI**


#### **Section 3 Pharmacogenomics 125**

#### Chapter 7 **Pharmacogenetics of Cardiovascular Disease: Genetic Variation and Statin Intolerance 127** Jana Petrkova, Milos Taborsky and Martin Petrek

Preface

effective and least toxic personalized therapy.

gan transplantation, and small populations.

This book is a self-contained collection of scholarly papers targeting the audience of aca‐ demics, scientists, physicians, pharmacists, practicing researchers, and postgraduate stu‐ dents whose work relates to genetic polymorphism and its application in individual-specific treatment. This book intends to provide readers with a comprehensive overview of genetic diversity and disease susceptibility, pharmacogenomics, ongoing advances in technology, and analytic methods in this field. It is divided into three sections with a total of eight chap‐ ters. These chapters are written by several authors: researchers, scientists, and experts in specific research fields related to genetic polymorphism. The editor would like to take this opportunity to thank all the authors for their valuable contributions. In fact, these chapters not only cover the overview of genetic polymorphism but also provide genetic diversity and disease susceptibility, as well as pharmacogenomics, which will help to optimize drug ther‐ apy, with respect to the patient's genotype, and will allow clinicians to determine the most

The first section contains two chapters related to genetic polymorphism, which describe polymorphisms at DNA level, type of polymorphisms, common DNA-based molecular

The second section consists of four chapters that focus on genetic diversity and disease sus‐ ceptibility, which include gene polymorphism in cancer, immunosuppressants in solid or‐

The third section includes two chapters on pharmacogenomics, which characterize the phar‐ macogenetics of cardiovascular disease and immunopharmacogenomics in cancer, describ‐ ing their population distribution and summarizing current knowledge on their biological plausibility. Clinical relevance and current guideline recommendations are also discussed.

**Yamin Liu**

China

Zhongda Hospital Southeast University

Department of Pharmacology

markers, and the major technique for DNA-based molecular marker detection.

#### Chapter 8 **Immunopharmacogenomics in Cancer Management 143** Gizem Calibasi-Kocal and Yasemin Baskin
